PharmaIN Corporation, headquartered in Seattle, WA, is a leading developer of affinity-based drug delivery solutions for biotech and pharmaceutical applications. Our business strategy focuses on developing superior drug therapies using our proprietary, novel drug delivery platform - on our own or with collaborators. Our technology can create innovative, value-added formulations for existing therapies, enable new discoveries (e.g. peptides), and can create and test new therapeutic strategies.

Our "Protected Graft Co-polymer" (PGC) drug delivery system uses proprietary carrier molecules and reversible "payload" binding chemistries (PhamaIN reversible binding, PRB™) to create new, innovative drug therapies for human disease. Using our technology we aim to enable new, value-added drug therapies or make "old" drugs better - more effective, easier to use, less toxic, and thus more competitive and valuable in the marketplace. Our current focus is on injected drugs. Mucosal delivery of our formulations (through the lungs or sublingual in the mouth) is anticipated in the future.

Our platforms can be used to enhance drug pharmacokinetics (i.e. how long a drug resides in the body, or "PK"), drug effectiveness, solubility and bioavailability (i.e. how much of a dose reaches the blood and is available to act therapeutically). Our technology can also target a drug to tissues with abnormal vascular permeability (e.g. tumor sites, inflammation). Our novel approach reduces chances for systemic toxicity by improving drug delivery to the intended site of action -- the specific target or receptor for the drug. Our technology can enable many drug candidates and is especially useful in combination with peptides - an untapped source of highly active agents that, until now, have been poor drug candidates due to susceptibility to enzyme degradation and rapid clearance by the body.